



Capromorelin

Worldwide Partnering Opportunity

1. Executive Summary

Capromorelin is one of the most advanced ghrelin receptor agonists, which was well characterized in clinical studies, particularly with a strong intellectual property position in GI motility disorders.

- Compound
 - Capromorelin tartarate (CP-424,391-18)
- Mechanism of Action (MOA)
 - A small molecule ghrelin receptor agonist, which functions as a ghrelin mimetic and induces growth hormone (GH) secretion
- Potential Target Indications
 - Cachexia and frailty*
 - Gastrointestinal (GI) motility disorders[†]
 - » Postoperative ileus (POI), gastroparesis, and gastroesophageal reflux disease (GERD)
- Medical Needs
 - Poor treatment options to address the underlying conditions in cachexia and frailty
 - No ideal single treatment of GI motility disorders – different MOA awaited

*: WO97/24369; †: EP1159964

1. Executive Summary (continued)

- Preclinical Profile
 - Highly potent ghrelin receptor ligand with a K_i of 6.7 nM
 - Oral activity demonstrated in animal models
 - Well tolerated in repeated dose toxicity studies
- Clinical Profile
 - A total of 18 clinical studies
 - Positive signals demonstrated
 - » Elevation of GH and insulin-like growth factor 1 (IGF-1) levels
 - » Efficacy on the number of esophageal reflux episodes
 - » Improvement on body composition and physical performance of older adults in a one-year trial
- Intellectual Property (IP)
 - Patents granted in major countries including US, EU, and Japan
 - Use patent for GI motility disorders has effects on other ghrelin receptor agonists.

2. Table of Contents

| Title | Slide No. |
|---------------------------------------------------|-----------|
| 1. Executive Summary | 2 |
| 2. Table of Contents | 4 |
| 3. Physiological Role of Ghrelin | 5 |
| 4. Potential Indications | 6 |
| 4.1. Proof of Concept of Capromorelin for Frailty | 7 |
| 5. Compound Attributes | 8 |
| 5.1. Non-Clinical Pharmacology | 9 |
| 5.2. Non-Clinical Pharmacokinetics | 11 |
| 5.3. Non-Clinical Safety | 12 |
| 5.4. Clinical Study | 13 |
| 5.5. Intellectual Properties | 14 |
| 6. Competitive Advantage | 15 |

弊社とのパートナーリングをご希望の方は「[お問い合わせ](#)」よりご連絡ください

ラクオリア創薬株式会社

Copyright RaQualia Pharma Inc. All Rights Reserved. 2011